These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

239 related items for PubMed ID: 26403919

  • 21. Peginterferon-α2a combined with response-guided short-term lamivudine improves response rate in hepatitis B e antigen-positive hepatitis B patients: a pilot study.
    Huang Z, Deng H, Zhao Q, Zheng Y, Peng L, Lin C, Zhao Z, Gao Z.
    Eur J Gastroenterol Hepatol; 2013 Oct; 25(10):1165-9. PubMed ID: 23571612
    [Abstract] [Full Text] [Related]

  • 22. Comparison of fibrosis regression of entecavir alone or combined with pegylated interferon alpha2a in patients with chronic hepatitis B.
    Chen S, Zhou J, Wu X, Meng T, Wang B, Liu H, Wang T, Zhao X, Kong Y, Wu S, Ou X, Jia J, Sun Y, You H.
    Hepatol Int; 2021 Jun; 15(3):611-620. PubMed ID: 33677771
    [Abstract] [Full Text] [Related]

  • 23. Durable hepatitis B surface antigen decline in hepatitis B e antigen-positive chronic hepatitis B patients treated with pegylated interferon-α2b: relation to response and HBV genotype.
    Sonneveld MJ, Rijckborst V, Cakaloglu Y, Simon K, Heathcote EJ, Tabak F, Mach T, Boucher CA, Hansen BE, Zeuzem S, Janssen HL.
    Antivir Ther; 2012 Jun; 17(1):9-17. PubMed ID: 22267464
    [Abstract] [Full Text] [Related]

  • 24. Hepatitis B virus surface antigen levels: a guide to sustained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis B.
    Brunetto MR, Moriconi F, Bonino F, Lau GK, Farci P, Yurdaydin C, Piratvisuth T, Luo K, Wang Y, Hadziyannis S, Wolf E, McCloud P, Batrla R, Marcellin P.
    Hepatology; 2009 Apr; 49(4):1141-50. PubMed ID: 19338056
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. [Analysis of the factors for predicting the outcomes of interferon-α and entecavir treatments for chronic hepatitis B with positive HBeAg].
    Xie Z, Zhou F, Zhou Y.
    Nan Fang Yi Ke Da Xue Xue Bao; 2013 Jun; 33(6):878-81. PubMed ID: 23803202
    [Abstract] [Full Text] [Related]

  • 27. Hepatitis B core-related antigen levels are associated with response to entecavir and peginterferon add-on therapy in hepatitis B e antigen-positive chronic hepatitis B patients.
    van Campenhout MJ, Brouwer WP, van Oord GW, Xie Q, Zhang Q, Zhang N, Guo S, Tabak F, Streinu-Cercel A, Wang J, Pas SD, Sonneveld MJ, de Knegt RJ, Boonstra A, Hansen BE, Janssen HL.
    Clin Microbiol Infect; 2016 Jun; 22(6):571.e5-9. PubMed ID: 26898481
    [Abstract] [Full Text] [Related]

  • 28. A randomized clinical trial of peginterferon alpha-2b with or without entecavir in patients with HBeAg-negative chronic hepatitis B: Role of host and viral factors associated with treatment response.
    Tangkijvanich P, Chittmittraprap S, Poovorawan K, Limothai U, Khlaiphuengsin A, Chuaypen N, Wisedopas N, Poovorawan Y.
    J Viral Hepat; 2016 Jun; 23(6):427-38. PubMed ID: 26387494
    [Abstract] [Full Text] [Related]

  • 29. Pegylated-interferon alpha therapy for treatment-experienced chronic hepatitis B patients.
    Yeh ML, Peng CY, Dai CY, Lai HC, Huang CF, Hsieh MY, Huang JF, Chen SC, Lin ZY, Yu ML, Chuang WL.
    PLoS One; 2015 Jun; 10(4):e0122259. PubMed ID: 25835020
    [Abstract] [Full Text] [Related]

  • 30. Association of hepatitis B core antibody level and hepatitis B surface antigen clearance in HBeAg-negative patients with chronic hepatitis B.
    Wang J, Zhang Z, Zhu L, Zhang Q, Zhang S, Pan Y, Liu J, Cao F, Fan T, Xiong Y, Yin S, Yan X, Chen Y, Zhu C, Li J, Liu X, Wu C, Huang R.
    Virulence; 2024 Dec; 15(1):2404965. PubMed ID: 39317345
    [Abstract] [Full Text] [Related]

  • 31. Peginterferon alpha versus other antiviral regimes for Chinese HBeAg-positive chronic hepatitis B patients.
    Deng Z, Wang C, Li Z, Li B, Liu S.
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2013 Dec; 38(12):1193-207. PubMed ID: 24384957
    [Abstract] [Full Text] [Related]

  • 32. Sustained immune control in HBeAg-positive patients who switched from entecavir therapy to pegylated interferon-α2a: 1 year follow-up of the OSST study.
    Han M, Jiang J, Hou J, Tan D, Sun Y, Zhao M, Ning Q.
    Antivir Ther; 2016 Dec; 21(4):337-44. PubMed ID: 26734984
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Pegylated interferon results in higher serological, but not virological, response rates when compared to continuous entecavir.
    Sonneveld MJ, Zoutendijk R, Hansen BE, Janssen HL.
    Antivir Ther; 2012 Dec; 17(8):1605-8. PubMed ID: 22898565
    [Abstract] [Full Text] [Related]

  • 36. Response-guided peginterferon therapy in hepatitis B e antigen-positive chronic hepatitis B using serum hepatitis B surface antigen levels.
    Sonneveld MJ, Hansen BE, Piratvisuth T, Jia JD, Zeuzem S, Gane E, Liaw YF, Xie Q, Heathcote EJ, Chan HL, Janssen HL.
    Hepatology; 2013 Sep; 58(3):872-80. PubMed ID: 23553752
    [Abstract] [Full Text] [Related]

  • 37. [A pilot study of peginterferon alfa-2a combined with short-term lamivudine therapy in HBeAg-positive chronic hepatitis B patients].
    Huang ZL, Zhao ZX, Deng H, Zhang YF, Lu CR, Gao ZL.
    Zhonghua Gan Zang Bing Za Zhi; 2010 Jun; 18(6):419-22. PubMed ID: 20587310
    [Abstract] [Full Text] [Related]

  • 38. [Quantifiable changes in HBeAg expression predict therapeutic efficacy of peg-interferon alfa-2a in patients with HBeAg-positive chronic hepatitis B].
    Ji YJ, Li FF, Ren WH, Zhu YH, Qin CY.
    Zhonghua Gan Zang Bing Za Zhi; 2013 May; 21(5):335-9. PubMed ID: 24025132
    [Abstract] [Full Text] [Related]

  • 39. Extended treatment with peginterferon α-2a in combination with lamivudine or adefovir for 96 weeks yields high rates of HBeAg and HBsAg seroconversion.
    Cao ZH, Ma LN, Zhang HW, Liu YL, Chen XY.
    J Dig Dis; 2013 Aug; 14(8):446-50. PubMed ID: 23615131
    [Abstract] [Full Text] [Related]

  • 40. Individualized treatment of HBeAg-negative chronic hepatitis B using pegylated interferon-α2a as first-line and week-12 HBV DNA/HBsAg stopping rule: a cost-effectiveness analysis.
    Iannazzo S, Coco B, Brunetto MR, Rossetti F, Caputo A, Latour A, Espinos B, Bonino F.
    Antivir Ther; 2013 Aug; 18(4):623-33. PubMed ID: 23486701
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 12.